$NKTR
Nektar Therapeutics Stock $nktr

$nktr Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000090670922000014 Filed on August 05, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$23.63M	$21.59M	$24.82M
YoY Change	-5.2%	-23.81%	4.97%
Cost Of Revenue	$4.972M	$5.115M	$5.315M
YoY Change	-6.38%	-33.29%	-7.66%
Gross Profit	$18.65M	$16.47M	$19.51M
YoY Change	-4.88%	-20.29%	9.03%
Gross Profit Margin	78.95%	76.3%	78.59%
Selling, General & Admin	$22.53M	$21.44M	$27.34M
YoY Change	-23.53%	-27.45%	-13.76%
% of Gross Profit	120.81%	130.19%	140.15%
Research & Development	$33.59M	$42.74M	$107.3M
YoY Change	-67.62%	-57.81%	12.18%
% of Gross Profit	180.08%	259.5%	549.82%
Depreciation & Amortization	$2.677M	$3.441M	$3.730M
YoY Change	-26.05%	-4.15%	6.57%
% of Gross Profit	14.35%	20.89%	19.12%
Operating Expenses	$33.59M	$42.74M	$107.3M
YoY Change	-67.62%	-57.81%	12.18%
Operating Profit	-$54.30M	-$152.8M	-$116.6M
YoY Change	-52.2%	38.68%	6.55%
Interest Expense	-$4.903M	-$6.132M	$26.29M
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$4.903M	-$6.132M	$26.29M
YoY Change	-69.35%	-59.0%	-295.01%
Pretax Income	-$59.20M	-$159.0M	-$90.27M
YoY Change	-54.32%	27.01%	-26.54%
Income Tax	-$155.0K	$100.0K	$126.0K
% Of Pretax Income
Net Earnings	-$59.05M	-$159.1M	-$90.39M
YoY Change	-54.47%	26.73%	-26.49%
Net Earnings / Revenue	-249.94%	-736.94%	-364.16%
Basic Earnings Per Share	-$0.31	-$0.85	-$0.49
Diluted Earnings Per Share	-$0.31	-$0.85	-$0.49
COMMON SHARES
Basic Shares Outstanding	187.4M shares	186.8M shares	185.8M shares
Diluted Shares Outstanding	187.6M shares	186.8M shares	185.8M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$546.4M	$619.3M	$667.0M
YoY Change	-40.68%	-38.07%	-35.7%
Cash & Equivalents	$105.8M	$77.55M	$67.99M
Short-Term Investments	$440.6M	$541.8M	$599.0M
Other Short-Term Assets	$22.51M	$19.25M	$20.83M
YoY Change	8.57%	52.79%	32.08%
Inventory	$19.06M	$16.97M	$15.38M
Prepaid Expenses
Receivables	$11.53M	$10.01M	$30.22M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$599.5M	$665.5M	$733.5M
YoY Change	-39.21%	-36.98%	-33.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$36.80M	$39.79M	$60.98M
YoY Change	-37.44%	-32.09%	4.22%
Goodwill	$76.50M	$76.50M	$76.50M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$8.928M	$37.36M
YoY Change	-100.0%	-84.45%	-61.12%
Other Assets	$2.323M	$2.234M	$1.521M
YoY Change	25.98%	549.42%	5.99%
Total Long-Term Assets	$181.5M	$196.5M	$290.7M
YoY Change	-37.64%	-37.67%	-18.7%
TOTAL ASSETS
Total Short-Term Assets	$599.5M	$665.5M	$733.5M
Total Long-Term Assets	$181.5M	$196.5M	$290.7M
Total Assets	$781.0M	$862.0M	$1.024B
YoY Change	-38.85%	-37.14%	-29.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.329M	$12.35M	$12.62M
YoY Change	-77.48%	-37.33%	-43.76%
Accrued Expenses	$78.66M	$92.64M	$92.66M
YoY Change	-32.37%	-16.78%	-8.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$83.99M	$105.0M	$105.3M
YoY Change	-39.99%	-19.87%	-14.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.054M	$2.080M	$2.704M
YoY Change	-21.06%	-48.21%	-34.53%
Total Long-Term Liabilities	$3.054M	$2.080M	$2.704M
YoY Change	-21.06%	-48.21%	-34.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$83.99M	$105.0M	$105.3M
Total Long-Term Liabilities	$3.054M	$2.080M	$2.704M
Total Liabilities	$368.8M	$403.3M	$416.2M
YoY Change	-22.48%	-13.53%	-9.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.142B	-$3.082B	-$2.923B
YoY Change	16.9%	20.52%	20.2%
Common Stock	$3.562B	$3.549B	$3.538B
YoY Change	1.99%	2.41%	3.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$412.2M	$458.7M	$607.9M
YoY Change
Total Liabilities & Shareholders Equity	$781.0M	$862.0M	$1.024B
YoY Change	-38.85%	-37.14%	-29.69%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$59.05M	-$159.1M	-$90.39M
YoY Change	-54.47%	26.73%	-26.49%
Depreciation, Depletion And Amortization	$2.677M	$3.441M	$3.730M
YoY Change	-26.05%	-4.15%	6.57%
Cash From Operating Activities	-$82.89M	-$74.99M	-$88.42M
YoY Change	-18.04%	-9.52%	14.71%
INVESTING ACTIVITIES
Capital Expenditures	-$181.0K	-$780.0K	$4.203M
YoY Change	-93.84%	-76.05%	46.14%
Acquisitions
YoY Change
Other Investing Activities	$111.6M	$84.93M	$134.5M
YoY Change	5198.01%	11.36%	911.14%
Cash From Investing Activities	$111.4M	$84.15M	$130.3M
YoY Change	-13521.08%	15.41%	1145.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	467.0K	$938.0K
YoY Change	-100.0%	-96.15%	-94.75%
NET CHANGE
Cash From Operating Activities	-82.89M	-74.99M	-$88.42M
Cash From Investing Activities	111.4M	84.15M	$130.3M
Cash From Financing Activities	0.000	467.0K	$938.0K
Net Change In Cash	28.51M	9.622M	$42.78M
YoY Change	-129.0%	348.16%	-187.67%
FREE CASH FLOW
Cash From Operating Activities	-$82.89M	-$74.99M	-$88.42M
Capital Expenditures	-$181.0K	-$780.0K	$4.203M
Free Cash Flow	-$82.71M	-$74.21M	-$92.63M
YoY Change	-15.78%	-6.8%	15.84%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0000906709
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-24006
	dei	Entity Registrant Name EntityRegistrantName	NEKTAR THERAPEUTICS
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	94-3134940
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 Mission Bay Boulevard South
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Francisco
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94158
	dei	City Area Code CityAreaCode	415
	dei	Local Phone Number LocalPhoneNumber	482-5300
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
	dei	Trading Symbol TradingSymbol	NKTR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	187404772	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77545000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	541771000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10006000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22492000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	16969000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	usd
CY2022Q2	us-gaap	Other Assets Current OtherAssetsCurrent	19245000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23333000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	665536000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	795581000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	8928000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39792000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	68996000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	117025000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	76501000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	76501000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2234000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2744000	usd
CY2022Q2	us-gaap	Assets Assets	861987000	usd
CY2021Q4	us-gaap	Assets Assets	1117189000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	12346000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9747000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	30323000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	15735000	usd
CY2022Q2	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	29234000	usd
CY2021Q4	nktr	Accrued Clinical Trial Expenses Current AccruedClinicalTrialExpensesCurrent	26809000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13035000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15468000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	20047000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	17441000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	104985000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85200000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	119415000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	125736000	usd
CY2022Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	27726000	usd
CY2022Q2	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	176775000	usd
CY2021Q4	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	195427000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2080000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3592000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	403255000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	437681000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q4	nktr	Preferred Stock Share Designated PreferredStockShareDesignated	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187405000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	185468000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	19000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	19000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3549360000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3516641000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8191000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4157000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3082456000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2832995000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	458732000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	861987000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1117189000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21585000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	28330000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46407000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51977000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5115000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7667000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10430000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	13423000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42740000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	101313000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	149993000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	196917000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20521000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29555000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	47860000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61234000	usd
CY2022Q2	us-gaap	Restructuring Charges RestructuringCharges	106045000	usd
CY2021Q2	us-gaap	Restructuring Charges RestructuringCharges	0	usd
	us-gaap	Restructuring Charges RestructuringCharges	107520000	usd
	us-gaap	Restructuring Charges RestructuringCharges	0	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	174421000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	138535000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	315803000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	271574000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-152836000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-110205000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-269396000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-219597000	usd
CY2022Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	usd
CY2021Q2	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-2713000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-4312000	usd
CY2022Q2	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	7228000	usd
CY2021Q2	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	13089000	usd
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	14757000	usd
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	26385000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1096000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	845000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1491000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2257000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6132000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14957000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	20161000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28440000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-158968000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-125162000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-249235000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-248037000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	357000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	226000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	449000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-159068000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-125519000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-249461000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-248486000	usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.34
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.34
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.37
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	186800000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	186800000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182698000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	182698000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	186323000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	186323000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	182038000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	182038000	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-159068000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-125519000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-249461000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-248486000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-988000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-64000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-3079000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-830000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-671000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-215000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-955000	usd
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-275000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1659000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-279000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4034000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1105000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-160727000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125798000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-253495000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-249591000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1077295000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17106000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23898000	usd
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123793000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	994506000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12553000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23714000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125798000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	904975000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	679508000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	188000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20961000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	607889000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-92768000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	467000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11103000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-160727000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	458732000	usd
	us-gaap	Profit Loss ProfitLoss	-249461000	usd
	us-gaap	Profit Loss ProfitLoss	-248486000	usd
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	33825000	usd
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	39254000	usd
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	14757000	usd
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	26385000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	33427000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-4312000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4951000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	5795000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47612000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32064000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7171000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	7090000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	57321000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-700000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4090000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12486000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-10018000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1168000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-676000	usd
	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-1486000	usd
	nktr	Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities	-2260000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-7627000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-11585000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2833000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2101000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	14588000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	14133000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-1520000	usd
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-4101000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-163417000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-159986000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	247014000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	527887000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	466423000	usd
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	612419000	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	5035000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4983000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6157000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	214426000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	83410000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	655000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	28523000	usd
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	750000	usd
	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	1500000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1405000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	30023000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-87000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-57000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	52327000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46610000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	25218000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198955000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	77545000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	152345000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1057000	usd
CY2022Q2	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	628200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Significant ConcentrationsOur customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balance contains billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements.We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, including as a result of the COVID-19 pandemic, our ability to develop and produce our drug candidates, our ability to supply comparator drugs for our clinical trials, or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, the COVID-19 pandemic or other factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if the COVID-19 pandemic or other factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.
CY2021Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77545000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25218000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	541771000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	708737000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	8928000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	64828000	usd
CY2022Q2	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	628244000	usd
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	usd
	nktr	Debt Investment Maximum Maturity Period DebtInvestmentMaximumMaturityPeriod	P2Y
	nktr	Debt Investment Maturity Term DebtInvestmentMaturityTerm	P1Y
CY2022Q2	us-gaap	Cash Cash	18726000	usd
CY2021Q4	us-gaap	Cash Cash	1250000	usd
CY2022Q2	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	628244000	usd
CY2021Q4	nktr	Cash Restricted Cash Cash Equivalents And Available For Sale Investments CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments	798783000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	700000	usd
CY2022Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2099000	usd
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3166000	usd
CY2022Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	13837000	usd
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	9342000	usd
CY2022Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1033000	usd
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3293000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	16969000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	15801000	usd
CY2022Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
	nktr	Royalty Monetization Proceeds RoyaltyMonetizationProceeds	274000000	usd
	nktr	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	-367277000	usd
	nktr	Non Cash Interest Expense Related To Sale Of Royalties NonCashInterestExpenseRelatedToSaleOfRoyalties	259030000	usd
	nktr	Partial Repayment Of Royalty Sale Proceeds PartialRepaymentOfRoyaltySaleProceeds	10000000	usd
	nktr	Gain Loss On Revaluation Of Liabilities Related To The Sale Of Future Royalties Gross GainLossOnRevaluationOfLiabilitiesRelatedToTheSaleOfFutureRoyaltiesGross	23522000	usd
CY2022Q2	nktr	Liability Related To Sale Of Potential Future Royalties Non Current LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent	179275000	usd
CY2022Q2	nktr	Liabilities On Sale Of Future Royalties Unamortized Transaction Costs LiabilitiesOnSaleOfFutureRoyaltiesUnamortizedTransactionCosts	2500000	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	5120000	usd
CY2022Q2	nktr	Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts	176775000	usd
CY2022Q1	us-gaap	Loss On Contract Termination LossOnContractTermination	1500000	usd
CY2022Q2	us-gaap	Business Exit Costs1 BusinessExitCosts1	20408000	usd
	us-gaap	Business Exit Costs1 BusinessExitCosts1	20408000	usd
CY2022Q2	us-gaap	Severance Costs1 SeveranceCosts1	27750000	usd
	us-gaap	Severance Costs1 SeveranceCosts1	27750000	usd
CY2022Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	57321000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	57321000	usd
CY2022Q2	us-gaap	Loss On Contract Termination LossOnContractTermination	566000	usd
	us-gaap	Loss On Contract Termination LossOnContractTermination	2041000	usd
CY2022Q2	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	106045000	usd
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	107520000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47612000	usd
	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	52201000	usd
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	57321000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	39792000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60510000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11103000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23714000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32064000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	85000	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	157000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	107000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	278000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.47
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.78
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.33
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.23
CY2022Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	1131000	shares
CY2021Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	1483000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	1937000	shares
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	3682000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20543000	shares
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18352000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21435000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18870000	shares

Files In Submission

Name	View Source	Status
0000906709-22-000014-index-headers.html	Edgar Link	pending
0000906709-22-000014-index.html	Edgar Link	pending
0000906709-22-000014.txt	Edgar Link	pending
0000906709-22-000014-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_0a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nktr-20220630.htm	Edgar Link	pending
nktr-20220630.xsd	Edgar Link	pending
nktr-20220630_cal.xml	Edgar Link	unprocessable
nktr-20220630_def.xml	Edgar Link	unprocessable
nktr-20220630_htm.xml	Edgar Link	completed
nktr-20220630_lab.xml	Edgar Link	unprocessable
nktr-20220630_pre.xml	Edgar Link	unprocessable
nktr2022-06x30xexx101ar201.htm	Edgar Link	pending
nktr2022-06x30xexx102north.htm	Edgar Link	pending
nktr2022-06x30xexx311.htm	Edgar Link	pending
nktr2022-06x30xexx312.htm	Edgar Link	pending
nktr2022-06x30xexx321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NKTR
Nektar Therapeutics Stock $nktr

2022 Q3 Form 10-Q Financial Statement

#000090670922000014 Filed on August 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR Nektar Therapeutics Stock $nktr

2022 Q3 Form 10-Q Financial Statement

#000090670922000014 Filed on August 05, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NKTR
Nektar Therapeutics Stock $nktr